Spinal Disc Therapy

Welcome to SpinalCyte

Lower Back Pain afflicts an estimated 10 million people annually in the US. Over 700,000 procedures are performed each year to treat Degenerative Disc Disease. Aging baby boomers may double those numbers in the next two decades. The current global spine market is estimated at $7.8B and projected to grow to $21B by 2017.

 

Back pain is strongly associated with degeneration of the intervertebral disc. Disc degeneration, although in many cases asymptomatic, is also associated with sciatica and disc herniation or prolapse. It alters disc height and the mechanics of the rest of the spinal column, adversely affecting the behavior of other spinal structures such as muscles and ligaments. In the long term, it can lead to spinal stenosis, a major cause of pain and disability in the elderly. Degenerated disc incidence is rising with current demographic changes and an increased aged population.


News & Events

July 20, 2017

SpinalCyte Announces New Japanese Patent Read More


April 27, 2017

SpinalCyte, LLC Receives New Australian Patent Read More


April 6, 2017

SpinalCyte, LLC Receives New European Patent Read More


March 14, 2017

First Fibroblast Injection Performed in SpinalCyte’s Landmark Trial for Spinal Disc Regeneration Read More


February 9, 2017

SpinalCyte Receives New U.S. Patent Read More


January 25, 2017

SpinalCyte Enrolls First Patient in Phase I Clinical Trial Read More


JANUARY 6, 2017

SpinalCyte, LLC Receives New U.S. Patent Read More


December 13, 2016

SpinalCyte, LLC Receives Institutional Review Board Approval for Phase I Clinical Trial Read More


May 4, 2016

SpinalCyte Receives New U.S. Patent for Biodegradable and Resorbable Structure Read More


April 22, 2016

SpinalCyte, LLC Receives New Canadian Patent for Spinal Disc Tissue Engineering Read More


April 19, 2016

SpinalCyte Announces Landmark Scientific Breakthrough From Phase II Animal Trials Read More 


April 15, 2016

SpinalCyte, LLC Announces Publication in Global Spine Journal Read More


March 29, 2016

SpinalCyte, LLC Announces New Results from Phase II Animal Trials of Cell Therapy to Regenerate the Spinal Disc Read More 


January 8, 2016

SpinalCyte, LLC Receives New Chinese Patent for Spinal Disc Tissue Engineering Read More 


October 25, 2015

SpinalCyte, LLC Presents at MENA Private Equity & Venture Capital Summit Read More 


October 14, 2015

SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering Read More


September 22, 2015

SpinalCyte Receives New U.S. Patent for Tissue Engineering Read More 


June 16, 2014

SpinalCyte, LLC Announces Final Animal Trials for Spinal Disc Tissue Engineering Read More 


May 20, 2014

SpinalCyte Receives U.S. Patent Read More


September 30, 2013

SpinalCyte, LLC Receives Australian Patent for Spinal Disc Tissue Engineering Read More 


July 11, 2013

SpinalCyte, LLC Receives Japanese Patent for Spinal Disc Tissue Engineering Read More 


 April 25, 2013

SpinalCyte Technology Wins Prestigious World Wide Best Science Award From ISASS Read More


February 6, 2013

SpinalCyte, LLC Reports the Addition of Jeffrey Geesin, Ph.D. to Clinical Advisory Board Read More 


November 9, 2012

SpinalCyte, LLC Profiled In Medical Device Daily Read More


November 5, 2012

SpinalCyte, LLC Receives U.S. Patent for Spinal Disc Regeneration Read More


October 22, 2012

May 9, 2012

SpinalCyte, LLC Reports Results From Animal Studies Read More 


December 16, 2011

SpinalCyte, LLC Receives Notice Of Acceptance on Australian Patent for Spinal Disc Tissue Engineering Read More 


July 11, 2011

SpinalCyte Publishes Initial Research Report On Spinal Disc Tissue Engineering Read More 


July 19, 2011

SpinalCyte, LLC Receives Notice Of Allowance on Chinese Patent for Spinal Disc Tissue Engineering Read More 


July 6, 2011

SpinalCyte, LLC Receives U.S. Patent for Spinal Disc Tissue Engineering Read More 

SpinalCyte